The North American oncolytic virus therapy market is estimated to grow at a CAGR of more than 16% during the forecast period. The market growth is attributed to the established research environment for various biotechnologies, the presence of major healthcare providers and growing healthcare investment in the US and Canada. Moreover, a growing number of cancer patients is augmenting the demand for oncolytic virus therapy. T-Vec (talimogene laherparepvec), is a recently approved oncolytic virus drug in the US and Europe. It is the second-generation oncolytic drug armed with GM-CSF to cure cancer. 

Visit for Global Oncolytic Virus Therapy Market Report at: https://www.omrglobal.com/industry-reports/oncolytic-virus-therapy-market

Research is undergoing other oncolytic virus drugs to cure cancer patients suffering from brain tumors along with breast, lung, liver and bladder cancer. There are other oncolytic virus drugs being researched which include JX-594 (pexastimogenedevacirepvec) for hepatocellular carcinoma, GM-CSF-expressing adenovirus CG0070 for bladder cancer, and Reolysin (pelareorep), a wild-type variant of reovirus for head and neck cancer.

The North America oncolytic virus therapy market is segmented into the US and Canada. The US holds the highest market share in the North American market. The major share of the US market is attributed to the FDA approval of the Imlygic therapy by Amgen Inc., that received approval in the US in 2015. In addition, the increasing prevalence of melanoma further contributes to the growth of the market in North America.

Further, the North American oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share of over 94% in 2018, whereas, adenoviruses-based therapy held the rest. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share.

The report covers the analysis of several players operating in the North American oncolytic virus therapy market. Some of the major players include Bristol-Myers Squibb Company, Abbvie Inc., Janssen Biotech Inc., Cold Genesys Inc., Cynvec LLC, and others. In December 2018, Bristol-Myers Squibb Company signed an agreement with PsiOxus Therapeutics, Ltd. to grant the company rights to NG-348, a pre-clinical stage, an armed oncolytic virus which addresses solid tumors. PsiOxus developed tumor-targeted delivery with oncolytic viruses’ platform, to target cancer and enable more patients to respond to treatment. The company has continued the study and development of immuno-oncology, which includes development in NG-348, in order to understand the potential of oncolytic viruses to boost checkpoint blockade in several types of cancer.

Research Methodology

The market study of the North American oncolytic virus therapy market is incorporated by extensive primary and secondary research conducted by the research team at OMR.  Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Authentic public databases such as the American Cancer Society, WHO, World Bank, and the National Institutes of Health.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for pharmaceutical and biopharmaceutical companies, healthcare organizations, research institutes and academics, investing companies, potential investors, government organizations and regulatory agencies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, different products, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation

1. North American Oncolytic Virus Therapy Market Research and Analysis by Product

2. North American Oncolytic Virus Therapy Market Research and Analysis by Application